Healthcare Management Solutions Ltd

hcsolutions.co.uk

Centrally based just south of Birmingham, HCMS has a nationwide team of Regional Managers, all of whom have had multi-site management experience and therefore have both practical experience and knowledge of day to day care home operation. We operate the lowest ratios of homes to Regional Managers in the industry recognising the intensive nature of the service that we offer.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact, Medical

NIMBLE THERAPEUTICS DELIVERS LEAD COMPOUNDS FOR TWO PROGRAMS UNDER COLLABORATION WITH LARGE PHARMA PARTNER, TRIGGERING MILESTONE PAYMENTS

Nimble Therapeutics | December 14, 2022

news image

Nimble Therapeutics Inc., a leading peptide therapeutics company, announced they have achieved discovery milestones for two programs partnered with a large pharma company. For each program, Nimble has delivered lead compounds ready for further pre-clinical testing and subsequent IND studies. As with all its partnered research programs, Nimble remains eligible for additional future pre-clinical, clinical, and commercial milestones, and royalties attached to each program as development progresses....

Read More

Cell and Gene Therapy

KRIYA ACQUIRES REDPIN THERAPEUTICS, ADDING NEUROLOGY PIPELINE TO GENE THERAPY PORTFOLIO

Kriya Therapeutics | November 17, 2022

news image

Kriya Therapeutics, Inc., a fully integrated gene therapy company advancing a broad portfolio of innovative therapeutics announced the acquisition of Redpin Therapeutics, Inc., a privately held biotechnology company developing regulatable gene therapies for intractable diseases of the nervous system. The acquisition serves as the foundation for Kriya’s neurology therapeutic area portfolio, with two lead gene therapy programs focused on epilepsy and trigeminal neuralgia. Redp...

Read More

MedTech, AI

EVAXION PRESENTS PROMISING RESULTS ON EVX-B1, AN AI-DESIGNED VACCINE AGAINST STAPHYLOCOCCUS AUREUS

Globenewswire | August 01, 2023

news image

Evaxion Biotech A/S a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies, presents promising results of EVX-B1 at the Staphylococcal Diseases Gordon Research Conference in New Hampshire, USA. “I am excited to present the impressive results of EVX-B1 at the Gordon Research Conference. The demonstration of full disease protection and complete bacterial clearance marks a significant advancement in the fight against...

Read More

Cell and Gene Therapy

EIGER BIOPHARMACEUTICALS PROVIDES UPDATE ON PLANS FOR EMERGENCY USE AUTHORIZATION APPLICATION FOLLOWING FDA FEEDBACK

Eiger BioPharmaceuticals, Inc. | October 06, 2022

news image

Eiger BioPharmaceuticals, Inc. a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, today announced that, following feedback from the U.S. Food and Drug Administration the company will not submit an emergency use authorization application of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19. Following Eiger's press release on September 6, 2022, the c...

Read More
news image

Industrial Impact, Medical

NIMBLE THERAPEUTICS DELIVERS LEAD COMPOUNDS FOR TWO PROGRAMS UNDER COLLABORATION WITH LARGE PHARMA PARTNER, TRIGGERING MILESTONE PAYMENTS

Nimble Therapeutics | December 14, 2022

Nimble Therapeutics Inc., a leading peptide therapeutics company, announced they have achieved discovery milestones for two programs partnered with a large pharma company. For each program, Nimble has delivered lead compounds ready for further pre-clinical testing and subsequent IND studies. As with all its partnered research programs, Nimble remains eligible for additional future pre-clinical, clinical, and commercial milestones, and royalties attached to each program as development progresses....

Read More
news image

Cell and Gene Therapy

KRIYA ACQUIRES REDPIN THERAPEUTICS, ADDING NEUROLOGY PIPELINE TO GENE THERAPY PORTFOLIO

Kriya Therapeutics | November 17, 2022

Kriya Therapeutics, Inc., a fully integrated gene therapy company advancing a broad portfolio of innovative therapeutics announced the acquisition of Redpin Therapeutics, Inc., a privately held biotechnology company developing regulatable gene therapies for intractable diseases of the nervous system. The acquisition serves as the foundation for Kriya’s neurology therapeutic area portfolio, with two lead gene therapy programs focused on epilepsy and trigeminal neuralgia. Redp...

Read More
news image

MedTech, AI

EVAXION PRESENTS PROMISING RESULTS ON EVX-B1, AN AI-DESIGNED VACCINE AGAINST STAPHYLOCOCCUS AUREUS

Globenewswire | August 01, 2023

Evaxion Biotech A/S a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies, presents promising results of EVX-B1 at the Staphylococcal Diseases Gordon Research Conference in New Hampshire, USA. “I am excited to present the impressive results of EVX-B1 at the Gordon Research Conference. The demonstration of full disease protection and complete bacterial clearance marks a significant advancement in the fight against...

Read More
news image

Cell and Gene Therapy

EIGER BIOPHARMACEUTICALS PROVIDES UPDATE ON PLANS FOR EMERGENCY USE AUTHORIZATION APPLICATION FOLLOWING FDA FEEDBACK

Eiger BioPharmaceuticals, Inc. | October 06, 2022

Eiger BioPharmaceuticals, Inc. a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, today announced that, following feedback from the U.S. Food and Drug Administration the company will not submit an emergency use authorization application of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19. Following Eiger's press release on September 6, 2022, the c...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us